CymaBay Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020

Rhea-AI Summary

CymaBay Therapeutics (NASDAQ: CBAY) will host a conference call on November 5, 2020, at 4:30 PM ET to discuss Q3 financial results and provide a business update. The company is focused on developing therapies for liver diseases and has a key product, seladelpar, which is under investigation for primary biliary cholangitis (PBC). Seladelpar has received orphan drug designation from the FDA and EMA, along with Breakthrough Therapy Designation from the FDA. For more information, visit their website.

Positive

• Seladelpar received orphan drug designation from FDA and EMA.
• Seladelpar obtained Breakthrough Therapy Designation from FDA.

Negative

• None.

NEWARK, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter and nine months ended September 30, 2020 and to provide a business update.

Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13709641. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.

About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need.  CymaBay is developing seladelpar, a potent, selective, orally active PPARδ agonist for patients with primary biliary cholangitis (PBC). For PBC, seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA.

For additional information about CymaBay visit www.cymabay.com.

Public Relations Contact:            

Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com

Investor Relations Contact:

Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com

 

FAQ

When is the CymaBay conference call for Q3 2020 results?

The conference call will be held on November 5, 2020, at 4:30 PM ET.

What is seladelpar being developed for?

Seladelpar is being developed for primary biliary cholangitis (PBC).

What regulatory designations has seladelpar received?

Seladelpar has received orphan drug designation, Breakthrough Therapy Designation from the FDA, and PRIority MEdicines status from the EMA.

How can I access the CymaBay conference call?

You can access the call by dialing 877-407-0784 from the U.S. or 201-689-8560 internationally, using Conference ID# 13709641.